Study of lymphoma that returned as slow-growing type
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 18 or older when you were first diagnosed with lymphoma.
- Your first lymphoma was either diffuse large B-cell lymphoma (with or without a slower-growing part) or a slow-growing lymphoma that later became aggressive.
- You received standard first treatment for diffuse large B-cell lymphoma.
- Your lymphoma returned as a slow-growing type between the years 2010 and 2020.
- Doctors have a copy of the biopsy report from when it came back, and medical records from both your first diagnosis and last checkups are available.
- You are willing to sign a consent form (or have one signed for you) so your medical information can be used for this research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at medical records of people with relapsed or refractory diffuse large B-cell lymphoma who received a combination of two drugs (tafasitamab and lenalidomide) through a special access program. The goal is to learn how well the treatment worked and what side effects occurred.
This study looks at genetic and molecular features of primary central nervous system diffuse large B-cell lymphoma to better understand the disease. It may help guide future treatments.
This study looks at a “Mixed Molecular Clinical Index” (MMCI), which combines test results from lymphoma tissue and clinical information. It aims to help better understand how diffuse large B-cell lymphoma behaves and how patients may respond to standard first-line treatment.
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
This study looks back at the medical records of people with lymphoma to learn more about the disease. It does not involve any new treatments or tests—just reviewing what happened in the past.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.